NCT03418038 2026-04-16
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Phase 2 Recruiting
Clinical Trials
40 trialsNCT04671667 2026-04-16
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07061977 2026-04-16
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT07532902 2026-04-16
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT01810913 2026-04-15
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2/3 Recruiting
NCT04267848 2026-04-15
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT05691478 2026-04-15
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
National Cancer Institute (NCI)
Phase 2/3 Recruiting
NCT06524544 2026-04-15
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06770582 2026-04-15
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04628767 2026-04-14
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
National Cancer Institute (NCI)
Phase 2/3 Recruiting
NCT06172296 2026-04-14
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT05019716 2026-04-13
Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT05172245 2026-04-13
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05198830 2026-04-13
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06029270 2026-04-13
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06064097 2026-04-13
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07195734 2026-04-13
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07281417 2026-04-13
Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05753306 2026-04-08
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
Mayo Clinic
Phase 2 Recruiting
NCT07097142 2026-04-08
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NRG Oncology
Phase 3 Recruiting
NCT03067181 2026-04-07
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Children's Oncology Group
Phase 3 Recruiting
NCT03583710 2026-04-07
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
M.D. Anderson Cancer Center
Phase 3 Recruiting
NCT05624996 2026-04-03
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NRG Oncology
Phase 3 Recruiting
NCT06050252 2026-04-03
Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06532279 2026-04-03
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NRG Oncology
Phase 2 Recruiting
NCT06145308 2026-04-02
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Peking Union Medical College
Phase 2 Recruiting
NCT07276360 2026-03-27
HypoRTCx-UG
Uganda Cancer Institute
Phase 2 Recruiting
NCT07498959 2026-03-27
TESTIGO
Sahlgrenska University Hospital
Phase NA Recruiting
NCT06323460 2026-03-24
Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT02734537 2026-03-23
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Eastern Cooperative Oncology Group
Phase 2 Recruiting
NCT03493425 2026-03-23
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
Eastern Cooperative Oncology Group
Phase 2 Recruiting
NCT03965234 2026-03-17
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
Roswell Park Cancer Institute
Phase 1/2 Recruiting
NCT05285358 2026-03-13
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
City of Hope Medical Center
Phase 1 Recruiting
NCT07174908 2026-03-03
A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
InxMed (Shanghai) Co., Ltd.
Phase 3 Recruiting
NCT03126916 2026-02-27
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
Phase 3 Recruiting
NCT05382338 2026-02-24
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
Children's Oncology Group
Phase 3 Recruiting
NCT05415709 2026-02-11
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer
Ohio State University Comprehensive Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT07082179 2026-02-11
A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer
Jiangsu Cancer Institute & Hospital
Phase 2 Recruiting
NCT07218913 2026-01-26
Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors
City of Hope Medical Center
Phase 1 Recruiting
NCT03467360 2026-01-20
ICAR
Centre Antoine Lacassagne
Phase 1 Recruiting